Abstracts tagged "psoriatic arthritis and clinical trials"

Abstract Number: 1818 • 2019 ACR/ARP Annual Meeting
Continuing versus Withdrawing Ixekizumab in Patients with Psoriatic Arthritis Who Achieved Sustained Minimal Disease Activity: Results from the SPIRIT-P3 Study
Laura Coates¹, Sreekumar Pillai ², Lu Zhang ², David Adams ², Lisa Kerr ², Maja Hojnik ², Gaia Gallo ², Ivo Valter ³, Hasan Tahir ⁴, Vinod Chandran ⁵, Philip Mease ⁶ and Arthur Kavanaugh ⁷, ¹Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom, ²Eli Lilly and Company, Indianapolis, IN, ³Center for Clinical and Basic Research, Tallinn, Estonia, ⁴Department of Rheumatology, Whipps Cross University Hospital, London, United Kingdom, ⁵Division of Rheumatology, University of Toronto, Krembil Research Institute, University Health Network, Toronto, ON, Canada, ⁶Swedish Medical Center/Providence St. Joseph Health and University of Washington, Seattle, WA, ⁷University of California, San Diego School of Medicine, La Jolla, CA
Background/Purpose: Psoriatic arthritis (PsA) is a chronic inflammatory disease that may lead to serious disability if not appropriately treated. Data on the effect of treatment…
Abstract Number: 2507 • 2019 ACR/ARP Annual Meeting
The Impact of Psoriasis Severity on Outcomes Among Psoriatic Arthritis Patients Receiving Adalimumab
Joseph Merola¹, Laura Coates ², Elizabeth M Lesser ³, Wendell C Valdecantos ³, Yanna Song ⁴ and Philip Mease ⁵, ¹Harvard Medical School, Brigham and Women’s Hospital, Boston, MA, ²University of Oxford, Oxford, United Kingdom, ³AbbVie Inc., North Chicago, ⁴AbbVie Inc., North Chicago, IL, USA, North Chicago, ⁵Swedish Medical Center/Providence St Joseph Health, and University of Washington, Seattle, WA
Background/Purpose: Psoriatic arthritis (PsA) is a heterogeneous, chronic, immune mediated disease associated with psoriasis (PsO), with varying skin severity which can range from mild to…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].